U.S. Non-oncology Biopharmaceuticals Market to Surpass US$ 253.0 Billion by 2026


SEATTLE, April 23, 2019 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the U.S. non-oncology biopharmaceuticals market size is estimated to be valued at US$ 116.0 Billion in 2018, and is projected to exhibit a CAGR of 10.2% over the forecast period (2018–2026).

Key Trends and Analysis of the U.S. Non-oncology Biopharmaceuticals Market: 

Frequent launch, approval, and robust pipeline of novel products in the U.S. is expected to support the U.S. non-oncology biopharmaceutical market growth over the forecast period.

For instance, in November 2018, Swedish Orphan Biovitrum AB and Novimmune SA received the U.S. Food and Drug Administration (FDA) approval for Gamifant (emapalumab-lzsg), an interferon gamma (IFNγ) blocking antibody for the treatment of pediatric (new born and older) and adult patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance to conventional HLH therapy.

Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/2575

In May 2018, Amgen Inc. received the U.S. Food and Drug Administration (FDA) approval for its Aimovig (erenumab-aooe) for the preventive treatment of migraine in adults.

Key players in the market are involved in strategic merger and partnership with other players for development of novel non-oncology biopharmaceuticals. For instance, in 2016, Teva Pharmaceutical Industries Ltd. and Celltrion, Inc. entered into an exclusive partnership to commercialize two of Celltrion’s mAb biosimilar candidates in the U.S. and Canada. Such strategic partnerships among key players is expected to support growth of the U.S. non-oncology biopharmaceuticals market growth over the forecast period.

Furthermore, factors which are expected to significantly affect the market growth, are increasing focus of government bodies on reducing the price of drugs in the U.S. Such actions by government bodies to reduce the drugs’ prices and also year-on-year price hikes is expected to be a factor negatively affecting the market value and overall U.S. non-oncology biopharmaceuticals market growth over the forecast period.

For instance, in November 2018, President Trump issued a proposal to reduce the price of drugs and to control price hikes by drugs manufacturers. Following the decision, key players such as Novartis AG, Sanofi S.A., and F. Hoffmann-La Roche AG etc. took No-Drug-Price-Increase Pledge and accepted to freeze hike on drug prices for the year 2018.

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/u-s-non-oncology-biopharmaceuticals-market-2575

Key Market Takeaways:

  • The market is expected to exhibit a CAGR of 10.2% during the forecast period (2018–2026). This growth is attributed to increasing launch, approval, and robust pipeline of novel non-oncology biopharmaceuticals drugs
  • The U.S. is the most lucrative market for monoclonal antibodies as most of the key players such as AbbVie Inc., Roche Holding AG, and Merck & Co. generate major revenue of their biological drugs from the U.S.
  • Recently, various blockbuster biologics such as Humira and Remicade lost patent in the U.S. market. Furthermore, various other high revenue generating biologics are expected to lose their patents in the near future. Loss of patents in the U.S. market offers lucrative opportunity to other players for development of biosimilars
  • Monoclonal antibody drug class is the most lucrative segment and is expected to account for major market share over the forecast period
  • High price of branded biologic products is expected to be a major factor negatively affecting its adoption, which in turn can hinder the market growth over the forecast period
  • Some of the major players operating in the U.S. non-oncology biopharmaceuticals market include, Sanofi S.A., Pfizer, Inc., Johnson & Johnson, Novartis International AG, Amgen, Inc., Eli Lilly and Company, AbbVie Inc., Bristol - Myers Squibb Company, F. Hoffmann-La Roche AG, Novo Nordisk A/S, GlaxoSmithKline plc., UCB Pharma, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Ltd, AstraZeneca Plc, Mylan N.V., LEO Pharma A/S, Boehringer Ingelheim GmbH, Alexion Pharmaceuticals Inc., Merck & Co., Inc., Elusys Therapeutics, Inc., Swedish Orphan Biovitrum AB, Samsung Bioepis NL B.V., Biogen Inc., and Theratechnologies Inc.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.


            

Contact Data